160 related articles for article (PubMed ID: 34304979)
1. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
Kumar C; Lakshmi PTV; Arunachalam A
J Mol Graph Model; 2021 Nov; 108():107919. PubMed ID: 34304979
[TBL] [Abstract][Full Text] [Related]
2. Structural studies of the PARP-1 BRCT domain.
Loeffler PA; Cuneo MJ; Mueller GA; DeRose EF; Gabel SA; London RE
BMC Struct Biol; 2011 Oct; 11():37. PubMed ID: 21967661
[TBL] [Abstract][Full Text] [Related]
3. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage.
Masson M; Niedergang C; Schreiber V; Muller S; Menissier-de Murcia J; de Murcia G
Mol Cell Biol; 1998 Jun; 18(6):3563-71. PubMed ID: 9584196
[TBL] [Abstract][Full Text] [Related]
4. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
[TBL] [Abstract][Full Text] [Related]
7. Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
Zuo X; Zhao H; Li D
J Mol Recognit; 2021 Jul; 34(7):e2891. PubMed ID: 33684965
[TBL] [Abstract][Full Text] [Related]
8.
Kam CM; Tauber AL; Oosthuizen DL; Levonis SM; Schweiker SS
Future Med Chem; 2020 Dec; 12(23):2105-2122. PubMed ID: 33225737
[No Abstract] [Full Text] [Related]
9. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
[TBL] [Abstract][Full Text] [Related]
13. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
14. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1.
Schreiber V; Amé JC; Dollé P; Schultz I; Rinaldi B; Fraulob V; Ménissier-de Murcia J; de Murcia G
J Biol Chem; 2002 Jun; 277(25):23028-36. PubMed ID: 11948190
[TBL] [Abstract][Full Text] [Related]
17. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
Kumar C; P T V L; Arunachalam A
Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors.
Zhou X; Yang Y; Xu Q; Zhou H; Zhong F; Deng J; Zhang J; Li J
Biochem Biophys Res Commun; 2022 Sep; 622():93-100. PubMed ID: 35843099
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Li N; Wang Y; Deng W; Lin SH
Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
[TBL] [Abstract][Full Text] [Related]
20. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Shah AP; Patel CN; Sureja DK; Sanghavi KP
Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
